Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xtant Medical Holdings (XTNT) EBIT Margin (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed EBIT Margin for 16 consecutive years, with 7.64% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 2116.0% to 7.64% in Q3 2025 year-over-year; TTM through Sep 2025 was 11.27%, a 2357.0% increase, with the full-year FY2024 number at 2.91%, up 821.0% from a year prior.
  • EBIT Margin was 7.64% for Q3 2025 at Xtant Medical Holdings, down from 13.06% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 21.51% in Q4 2024 to a low of 14.14% in Q1 2022.
  • A 5-year average of 4.6% and a median of 8.78% in 2023 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -1794bps in 2022, then surged 3505bps in 2024.
  • Xtant Medical Holdings' EBIT Margin stood at 6.65% in 2021, then crashed by -270bps to 11.29% in 2022, then dropped by -20bps to 13.54% in 2023, then surged by 259bps to 21.51% in 2024, then plummeted by -64bps to 7.64% in 2025.
  • Per Business Quant, the three most recent readings for XTNT's EBIT Margin are 7.64% (Q3 2025), 13.06% (Q2 2025), and 3.23% (Q1 2025).